Combination of Corynebacterium Parvum and Cytostatic Drugs in Disseminated Human Cancers
It is now known that C. parvum is a very potent experimental immunopotentiator that can increase macrophage production, increase phagocytosis and activation of macrophages, and activate the alternate pathway of complement. It also induces lymphocyte trapping and increases antibody production against both T-cell dependent and T-cell independent antigens, whereas it decreases GVH reactions and, in certain conditions, PHA transformation. C. parvum has also been shown to increase the production of colony stimulating factor. These properties explain why C. parvum has shown potent antitumor activity in a variety of animal systems, including T-cell deprived mice and has shown also synergism with cytostatic agents when applied to disseminated tumors.
KeywordsImmune Parameter Cytostatic Drug Cytostatic Agent Immune Competence Potent Antitumor Activity
Unable to display preview. Download preview PDF.
- 1.ISRAEL L. et HALPERN B.: Le corynebacterium dans les cancers avancés. — N. Presse Méd, 1972, 1, 19–23.Google Scholar
- 2.ISRAEL L.: A randomized study of chemotherapy versus chemotherapy and immune therapy with corynehacterium parvum in advanced breast cancer. — in: Conferences, Symposium, Workshops of the XIth International Cancer Congress. Vol. I. 222–223. 1974. Florence. Ambrosiana Milano Ed.Google Scholar
- 3.ISRAEL L.: Non specific immuno-stimulation in bronchogenic cancer. — Scand. J. Resp. Dis. Suppl. 89, 95–105, 1974.Google Scholar
- 4.ISRAEL L., EDELSTEIN R., DEPIERRE A. and DIMITROV N.: Brief communication: Daily intravenous infusions of corynebacterium parvum in twenty patients with disseminated cancer: A preliminary report of clinical and biologic findings. — Journal of the National Cancer Institute, 1975, (in press).Google Scholar